Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:1303-1308

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bengtsson, K.
Right arrow Articles by Groop, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bengtsson, K.
Right arrow Articles by Groop, L.
Related Collections
Right arrow Other hypertension
Right arrow Type 2 diabetes
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease

(Hypertension. 2001;37:1303.)
© 2001 American Heart Association, Inc.


Scientific Contributions

ß2-Adrenergic Receptor Gene Variation and Hypertension in Subjects With Type 2 Diabetes

Kristina Bengtsson; Marju Orho-Melander; Olle Melander; Ulf Lindblad; Jonas Ranstam; Lennart Råstam; Leif Groop

From the Department of Endocrinology (K.B, M.O.M., O.M., L.G.) and Department of Community Medicine (U.L. L.R.), Malmö University Hospital, Lund University, Malmö, Sweden; Billingen Health Care Center (K.B.), Skövde, Sweden; Skaraborg Institute (U.L.), Skövde, Sweden; and Malmö University (J.R.), Malmö, Sweden.

Correspondence and reprint requests to K. Bengtsson, MD, Billingen Health Care Center, Ekängsvägen 15, S-541 40 Skövde, Sweden. E-mail kristina.a.bengtsson{at}vgregion.se


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—The aim of this study was to investigate whether polymorphisms in the ß2-adrenergic receptor gene (5'LC-Arg19Cys, Arg16Gly, Gln27Glu) are associated with hypertension in patients with or without type 2 diabetes and with the blood pressure levels in normotensive sib pairs. The association study included 291 hypertensive patients without type 2 diabetes, 124 hypertensive patients with type 2 diabetes, and 265 healthy control subjects from Sweden. In addition, normotensive sib pairs that were discordant for the Arg16Gly (72 pairs) and Gln27Glu (40 pairs) polymorphisms were identified in type 2 diabetes families from Finland. Genotyping was performed using polymerase chain reaction–restriction fragment-length polymorphism analysis. Homozygous carriers of the Arg16 allele had a significantly increased odds ratio (OR) for hypertension in patients with type 2 diabetes (OR 2.14; 95% confidence interval [CI], 1.05 to 4.33), particularly among lean (body mass index<27 kg/m2) patients (OR 3.47; 95% CI, 1.06 to 11.33). The Gln27 allele showed a weaker association to hypertension (OR 1.55; 95% CI, 1.00 to 2.41) and was found to be in linkage disequilibrium with the Cys19 allele of the 5'LC-Arg19Cys polymorphism. In the paired-sibling analysis, siblings with at least 1 copy of the Arg16 allele had higher systolic blood pressure (P=0.049), and nondiabetic siblings had a higher body mass index (P=0.026) than siblings homozygous for the Gly16 allele. These results indicate that the Arg16 allele of the ß2-adrenergic receptor gene confers an increased risk for hypertension in subjects with type 2 diabetes and is associated with higher blood pressure levels and higher body mass index in sib pairs who are discordant for the polymorphism.


Key Words: genetics • hypertension, genetic • blood pressure • diabetes • receptors, adrenergic, beta • sibling


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The ß2-adrenergic receptors (B2AR) are G-protein coupled receptors, which are widely distributed in the body, and they mediate vasodilatation, bronchial dilatation, and lipolysis.1 2 Three common polymorphisms in the B2AR gene on chromosome 5q31 to 32 have been reported: Arg16Gly, Gln27Glu, and 5'LC-Arg19Cys.3 4 Several studies have investigated the role of these polymorphisms in asthma,5 obesity,6 7 and hypertension.8 9 10 Whereas the findings in asthma have been consistent,11 the relationship between these polymorphisms and hypertension and obesity is unclear.

The Gly16 allele of the Arg16Gly polymorphism has been ascribed a greater degree of agonist-induced downregulation of the receptor in transfected fibroblasts and human bronchial smooth muscle12 but also with a 5-fold increased sensitivity to catecholamine-induced lipolysis in human adipocytes.6 The Gly16 allele has been associated with hypertension in African Caribbeans8 and with elevated blood pressure and reduced vasodilatation after infusion of salbutamol in normotensive Austrian males.13 However, the Arg16 allele has been associated with elevated blood pressure in the offspring of Norwegians9 and Germans.10 Although the Gln27Glu polymorphism has been associated with obesity,6 7 14 type 2 diabetes, and hypertriglyceridemia,15 these findings have not been replicated in other studies.16 17 The Gln27Glu polymorphism is in linkage disequilibrium with the 5'LC-Arg19Cys polymorphism in the 5'-leader cistron (5'LC).4 The 5'LC codes for a polypeptide that seems to affect the expression of the receptor18 and could therefore influence the susceptibility to hypertension,4 obesity, and type 2 diabetes.19

The aim of this study was to investigate the role of the Arg16Gly, Gln27Glu, and 5'LC-Arg19Cys polymorphisms in the B2AR gene in hypertension and type 2 diabetes in a case-control association study and in genotype-discordant sibling pairs.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
For the case-control association study, we enrolled 291 unrelated hypertensive patients without type 2 diabetes and with age at onset of <=60 years and 265 unrelated healthy control subjects without medication, personal history of hypertension, first-degree family history of hypertension, or type 2 diabetes from southern Sweden.20 The subjects identified in the Skaraborg Hypertension and Diabetes Project consisted of 2 cohorts. One cohort included 1149 patients with hypertension and/or diabetes and the other cohort included an age-stratified, random sample (1400 invited, 1109 participating) from the population 40 years of age and older. Hypertensive patients and normotensive spouses from 250 families were recruited from healthcare centers in the Scania region. In addition, 124 unrelated hypertensive patients with type 2 diabetes were ascertained from the Skaraborg Hypertension and Diabetes project.21 Three subjects were excluded because of genotyping failure and misclassification. Hypertension was defined as 3 consecutive blood pressure measurements >=160 mm Hg (systolic blood pressure) and/or >=90 mm Hg (diastolic blood pressure) or ongoing antihypertensive treatment. The control subjects had systolic and diastolic blood pressures <=150 mm Hg and <=80 mm Hg, respectively. The diagnosis of type 2 diabetes was based on criteria from the World Health Organization.22 The participants were categorized as follows:1 all hypertensives are patients with hypertension, regardless of whether they had type 2 diabetes or not (n=415);2 hypertensives without type 2 diabetes (n=291);3 hypertensives with type 2 diabetes (n=124); and4 healthy controls (n=265) (Table 1).


View this table:
[in this window]
[in a new window]
 
Table 1. Clinical Characteristics of Individuals in the Case-Control Association Study and in the Genotype-Discordant Sib-Pair Study

For the genotype-discordant sib pair study, 494 normotensive siblings were ascertained from 118 families with type 2 diabetes in Botnia, Finland,23 and they were genotyped for the B2AR gene Arg16Gly and Gln27Glu polymorphisms to identify genotype discordant pairs. In total, we identified 72 sib pairs in which 1 of the siblings was homozygous for the Gly16 allele and the other sibling carried either 1 or 2 Arg16 alleles. Similarly, we identified 40 sib pairs in which 1 of the siblings was homozygous for the Glu27 allele whereas the other sibling had 1 or 2 Gln27 alleles. The 72 sib pairs who were discordant for Arg16Gly polymorphism originated from 46 sibships that comprised 118 individuals, and the 40 sib pairs who were discordant for the Gln27Glu polymorphism originated from 26 sibships and included 64 individuals (Table 1). The ethics committees of the Gothenburg and Lund University approved the study. Informed consent was obtained from all the participants.

Blood pressure was measured with a sphygmomanometer after 5 minutes of rest in the supine position in the Swedish subjects and twice within 10 minutes after 15 minutes of rest in the sitting position in the Finnish subjects, the values given are the averages of the 2 measurements. Body weight and height were measured and body mass index (BMI) was calculated. BMI >=27 kg/m2 was considered as overweight. Total genomic DNA was extracted from the whole blood by standard methods.24

The Arg16Gly and Gln27Glu polymorphisms were genotyped by polymerase chain reaction and restriction fragment-length polymorphism methods. The Arg16Gly polymorphism was amplified in a genomic 203-bp fragment using primers ß2 to 16-MM-F (5'-CGCCTTCTTGCTGGCACGCAAT) and ß2 to 16/27-R (5'-CCAGTGAAGTGATGAAGTAGTT), of which the former contains a nucleotide mismatch (underlined) to create a BsrDl recognition site in case of the Gly16 allele. The Gln27Glu polymorphism was amplified in a genomic 169-bp fragment with primers ß2 to 27-MM-F (5'-CCGGACCACGACGTCACCCAG) and ß2 to 16/27-R, of which the former contains a nucleotide mismatch (underlined) to create a BstNl recognition site in case of the Glu27 allele. The primers were designed according to the published B2AR cDNA sequence.1 PCR reactions were performed with 50 ng of genomic DNA in a total volume of 20 µL containing 10 pmol of each primer, 4 nmol dNTPs, 0.5 U Taq polymerase (Pharmacia) in 1x (NH4)2SO4-buffer (16 mmol/L [NH4]2SO4; 67 mmol/L Tris, pH 8.8; 0.01% Tween), with 3% formamide, and 1.5 mmol/L MgCl2. PCR conditions were as follows: initial denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation (94°C for 30 seconds), annealing (60°C for 30 seconds), and extension (72°C for 30 seconds), with the final extension at 72°C for 10 minutes. The PCR products were digested for 2 hours at 60°C using the buffers recommended by the manufacturer. The product containing the Arg16Gly polymorphism was digested with 1 U of BsrDl (New England Biolabs), which produced 2 fragments of 22 and 181 bps in case of the Gly16 allele, leaving the Arg16 allele uncut. The product containing the Gln27Glu polymorphism was digested with 1 U of BstNl (New England Biolabs), which resulted in 2 fragments of 95 and 75 bps in case of Gln27 allele and 3 fragments of 20, 58, and 95 bps in case of the Glu27 allele. The fragments were separated on 4.5% multipurpose agarose gel (Appligene) with ethidium bromide and visualized under ultraviolet light.

A genomic 172-bp fragment containing the 5'LC-Arg19Cys polymorphism was PCR amplified with a forward primer 5'-GAATGAGGCTTCCAGGCGTCC and a reverse primer 5'- GTCGTGGTCCGGCGCATGGC. PCR reactions were performed with 50 ng of genomic DNA in a total volume of 20 µL containing 10 pmol of each primer, 2 nmol dNTPs, 0.5 U Taq polymerase (Amersham Pharmacia) in a PCR buffer recommended by the manufacturer (Pharmacia) with 1.5% formamid. PCR conditions were as follows: initial denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation (94°C for 30 seconds), annealing (65°C for 30 seconds), and extension (72°C for 30 seconds), with the final extension at 72°C for 10 minutes. The PCR products were digested in a total volume of 30 µL for 3 hours at 37°C with 1 U of MspA1I restriction endonuclease (Promega) in a buffer recommended by the manufacturer. The MspA1I cuts the 5'LC-Arg19 allele to fragments of 144 and 54 bps, whereas the 5'LC-Cys19 allele remains intact. The fragments were separated on 4.5% multipurpose agarose gel (Appligene) with ethidium bromide and visualized under ultraviolet light.

Statistical Methods
Results are presented as mean±SD. Differences between group means were tested by ANCOVA. Association between genotypes and hypertension was analyzed by logistic regression and expressed as odds ratio (OR) with 95% confidence interval (CI) and with the Gly16Gly and Glu27Glu genotypes as reference. Data from the genotype-discordant sib pairs were analyzed using a modified permutation test for paired replicates.25 26 The 2-tailed probability value was estimated using a large (107) random sample from all possible permutations. If the observed sum of differences entered into the 5% region of rejection, the difference between pairs was considered statistically significant. For sib pairs discordant for the Arg16Gly polymorphism, the differences in phenotypic variables were computed as the values in the sibling with the Arg16Arg or Gly16Arg genotype minus the value in the sibling with the Gly16Gly genotype. For sib pairs discordant for the Gln27Glu polymorphism, the differences were computed as the values in the sibling with the Gln27Gln or Gln27Glu genotype minus the value in the sibling with the Glu27Glu genotype. Analyses, except the permutation tests, were performed using BMDP Statistical Software version 1.12 and an SPSS statistical program (SPSS/PC+ for the IBM-PC/XT/AT, 1986). All statistical tests were 2-sided, and P<0.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
In the Swedish population, the genotype frequencies for the Arg16Gly polymorphism in the B2AR gene were 13.4% for Arg16Arg, 45.6% for Arg16Gly, and 41.0% for the Gly16Gly genotype, and the genotype frequencies for the Gln27Glu polymorphism were 30.1% for Gln27Gln, 48.5% for Gln27Glu, and 21.3% for the Glu27Glu genotype. This is in accordance with the genotype frequencies reported in other European populations.4 The observed genotype frequencies in the different study groups were in Hardy-Weinberg equilibrium. The codon 16 and 27 polymorphisms were in linkage disequilibrium in the Swedish population: 100% of the Arg16-carrying chromosomes had Gln at position 27, whereas 28% of the Gly16-carrying chromosomes had Gln and 72% had Glu in position 27. The 5'LC-Arg19Cys polymorphism was in tight linkage disequilibrium with the Gln27Glu polymorphism; the Cys19 allele was associated with the Gln27 allele in all but 1 (n=1112) chromosome.

There was a significant increase in the OR (OR 2.14; 95% CI, 1.05 to 4.33, P=0.035) for hypertension in the Arg16Arg genotype carriers with type 2 diabetes (Table 2). Similarly, there was an increase in the OR for hypertension in the Gln27Gln genotype carriers (OR 1.55; 95% CI, 1.00 to 2.41, P=0.050). Neither the Arg16 nor the Gln27 allele conferred an increased risk for hypertension in subjects without type 2 diabetes. The carriers of the different genotypes showed no statistically significant difference between the serum creatinine values and the occurrence of proteinuria. The Arg16Arg genotype was associated with hypertension, especially in the nonobese (BMI<27 kg/m2) subgroup of patients with hypertension and type 2 diabetes (OR 3.47; 95% CI, 1.06 to 11.33, P=0.040).


View this table:
[in this window]
[in a new window]
 
Table 2. OR for All HT and for HT With and Without Type 2 Diabetes for the Arg16Gly and Gln27Glu Polymorphisms in B2AR Gene

Among the sib pairs discordant for the Arg16Gly polymorphism, those siblings carrying 1 or 2 Arg16 alleles had higher systolic blood pressure compared with individuals homozygous for the Gly16 allele (P=0.049, Table 3). Among the nondiabetic pairs (n=54), siblings with 1 or 2 Arg16 alleles had a higher BMI than siblings homozygous for Gly16 (P=0.026). This was due to the male siblings (11 pairs), 25.9 kg/m2 versus 24.4 kg/m2 (P=0.018). Figure 1 shows the difference in blood pressure and BMI of the individuals in the sib pair combinations used in the permutation test. There was a significant difference in systolic blood pressure between the siblings and in BMI in nondiabetic siblings homozygous for the Gly16 allele and carriers of 1 or more Arg16 alleles.


View this table:
[in this window]
[in a new window]
 
Table 3. Differences in Clinical Characteristics of Siblings Discordant for the Arg16Gly and Gln27Glu Polymorphisms Analyzed by the Permutation Test



View larger version (24K):
[in this window]
[in a new window]
 
Figure 1. Clinical characteristics of the sib pairs discordant for the Arg16Gly polymorphism of the ß2-adrenergic receptor gene. *P=0.049; **P=0.026.

There were no significant differences in blood pressure levels or BMI between siblings discordant for the Gln27Glu polymorphism.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The key finding of the present study was an increased risk for hypertension in type 2 diabetic carriers of the Arg16 and Gln27 alleles of the B2AR gene. This increased risk was not due to differences in nephropathy between the carriers. We also found that normotensive siblings from families with type 2 diabetes carrying 1 or 2 Arg16 alleles had a higher systolic blood pressure and a higher BMI compared with siblings homozygous for Gly16 allele. Because the B2AR regulates blood pressure as well as glucose and fat metabolism, we tested the B2AR polymorphisms for association with hypertension as well as diabetes and obesity. Some caution in interpretation of the data is warranted because we performed more than 1 test. The observed association between hypertension and the Arg16 allele is in accordance with a previous report in Scandinavians.9 In addition, a recent study in German twins showed that the Arg16 allele was associated with higher systolic blood pressure levels.10 On the other hand, Gratze et al found that young normotensive white male subjects homozygous for the Gly16 allele had higher blood pressure and decreased peripheral vasodilatation in response to salbutamol infusion.13 In addition, an association between the Gly16 allele and hypertension has been reported in African Caribbeans.8 Salt-sensitive individuals show a greater downregulation of the B2AR in response to high-salt intake.27 Black Africans are known to be more salt sensitive than whites,28 which has been proposed to explain the association between hypertension and the Gly16 allele in African Caribbeans.8

There are several other polymorphisms in the vicinity of the Arg16Gly polymorphism, such as the 5'LC-Arg19Cys, Gln27Glu, and Thr164Ile. Unfortunately, previous studies have not taken linkage disequilibrium between these polymorphisms into account. In vitro the 5'LC-Cys19 allele has been associated with an increase in B2AR gene expression, the Glu27 allele has been associated with a resistance to downregulation, the Ile164 allele has been associated with an impaired Gs-protein coupling,12 and the Arg16 allele has been associated with decreased receptor density on the surface of cultured human fibroblasts.29 Liggett and coworkers reported that the Gly16 allele is associated with increased agonist-induced downregulation of the B2AR in Chinese hamster fibroblasts and that the effect of the Gly16 allele dominates when combined with the Glu27 allele.12 Interestingly, the Glu27 allele has otherwise been shown to be resistant to agonist-induced downregulation.30

In this study we found that the haplotype LC-Cys19-Arg16-Gln27 was associated with increased risk for hypertension in the case-control association study and with elevated systolic blood pressure and higher BMI in genotype-discordant sib pairs. The allele frequencies of the polymorphisms in the B2AR gene differ between different populations.31 The findings that the Arg16 allele is associated with hypertension and higher blood pressure levels in Scandinavians, whereas the Gly16 allele is associated with hypertension in other populations,8 13 may suggest that it is not the Gly16Arg polymorphism per se but rather some polymorphism in linkage disequilibrium with the Gly16Arg polymorphism that is responsible for the association.

Because of the well-established link between hypertension and obesity, we also analyzed BMI in relation to codon 16 and 27 genotypes. We observed that the Arg16 allele was associated with a higher BMI in the sib-pair study. This is not surprising because of the strong linkage disequilibrium between the Gly16Arg and Gln27Glu polymorphisms. Several studies have shown that the Glu27 allele is associated with obesity.6 15 19 However, other studies have found the Gln27 allele to be associated with obesity in males.7 32 Our data are in accordance with a predominant role of the B2AR gene in promoting obesity in males. The difference in BMI in sib pairs was restricted to male subjects with the Arg16 allele.

In conclusion, the Arg16 and Gln27 alleles of the B2AR gene confer an increased risk for hypertension in nonobese patients with type 2 diabetes. This association was replicated in a sib-pair analysis showing that siblings with 1 or 2 Arg16 alleles had higher systolic blood pressure levels and BMI than siblings homozygous for the Gly16 allele.


*    Acknowledgments
 
This research was funded by Swedish Heart Lung Foundation; the Swedish Medical Research Council; National Public Health Institute; Skaraborg Institute; Skaraborg County Council, West Region County; the Region Skane; the Faculty of Medicine, Lund University; the Påhlsson Foundation, Malmö University Hospital; the Ernhold Lundström and the Crafoord Foundations; and the NEPI Foundation (The Swedish Network of Pharmacoepidemiology). The Botnia Study was supported by grants from the Sigrid Juselius Foundation, Academy of Finland, Swedish Medical Research Council, and European Economic Community Paradigm (BM44-CT95-0662). We are most grateful to Ann Carlsson, Agneta Edman, and Lena Rosberg for excellent technical assistance.

Received May 25, 2000; first decision June 21, 2000; accepted October 30, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Kobilka BK, Dixon RAF, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. cDNA for the human ß2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci. 1987;84:46–50.[Abstract/Free Full Text]

2. Swales JD, ed. Textbook of Hypertension. Oxford, England: Blackwell Scientific Publisher;1994.

3. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the ß2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334–339.

4. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5'leader cistron of the human ß2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927–1932.[Medline] [Order article via Infotrieve]

5. Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human ß2-adrenergic receptor structure. Pulm Pharmacol. 1995;8:1–10.[Medline] [Order article via Infotrieve]

6. Large V, Hellström L, Reynisdottir S, Lönnquist F, Eriksson P, Lannfeldt L, Arner P. Human Beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte Beta-2 adrenoceptor function. J Clin Invest. 1997;100:3005–3013.[Medline] [Order article via Infotrieve]

7. Hellström L, Large V, Reynisdottir S, Wahrenberg H, Arner P. The different effects of a Gln27Glu ß2-adrenoceptor gene polymorphism on obesity in males and in females. J Intern Med. 1999;245:253–259.[Medline] [Order article via Infotrieve]

8. Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJL, Skrabal F, Caulfield M. Essential hypertension in African Caribbeans associates with a variant of the ß2-adrenoceptor. Hypertension. 1997;30:773–776.[Abstract/Free Full Text]

9. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P, Li G-H, Schuster H, Wienker TF, Hoehe MR, Lund-Johansen P. ß2-Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int. 1998;53:1455–1460.[Medline] [Order article via Infotrieve]

10. Busjahn A, Li G-H, Faulhaber H-D, Rosenthal M, Becker A, Jeschke E, Schuster H, Timmermann B, Hoehe MR, Luft FC. ß2-Adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension. 2000;35:555–560.[Abstract/Free Full Text]

11. Dewar JC, Wheatley AP, Venn A, Morrison JFJ, Britton J, Hall IP. ß2-Adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy. 1998;28:442–448.[Medline] [Order article via Infotrieve]

12. Liggett S. Molecular and genetic basis of ß2-adrenergic receptor function. J Allergy Clin Immunol. 1999;104:S42–S46.[Medline] [Order article via Infotrieve]

13. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, Luft FC, Hoehe MR, Skrabal F. ß2-Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999;33:1425–1430.[Abstract/Free Full Text]

14. Mori Y, Kim-Motoyama H, Ito Y, Katakura T, Yasuda K, Ishiyama-Shigemoto S, Yamada K, Akanuma Y, Ohashi Y, Kimura S, Yazaki Y, Kadowaki T. The Gln27Glu ß2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Biochem Biophys Res Commun. 1999;258:138–140.[Medline] [Order article via Infotrieve]

15. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the ß2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia. 1999;42:98–101.[Medline] [Order article via Infotrieve]

16. Kortner B, Wolf A, Wendt D, Beisiegel U, Evans D. Lack of association between a human ß-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. Int J Obesity. 1999;23:1099–1100.[Medline] [Order article via Infotrieve]

17. Echwald SM, Sörensen TIA, Tybjaerg-Hansen A, Andersen T, Pedersen O. Gln27Glu variant of the human ß2-adrenoceptor gene is not associated with early-onset obesity in Danish men. Diabetes. 1998;47:1657–1658.[Medline] [Order article via Infotrieve]

18. Parola AL, Kobilka BK. The peptide product of a 5'leader cistron in the ß2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 1994;269:4497–4505.[Abstract/Free Full Text]

19. Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan X, Koyanagi A, Koyama W, Nonaka K. Polymorphism in the 5'-leader cistron of the ß2-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocrinol Metab. 1999;84:1754–1757.[Abstract/Free Full Text]

20. Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Råstam L, Groop L, Hulthén UL. Role of the Gly460Trp polymorphism of the {alpha}-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens. 2000;14:43–46.[Medline] [Order article via Infotrieve]

21. Bög-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and NIDDM: The Skaraborg Hypertension Project. J Int Med. 1998;243:223–232.[Medline] [Order article via Infotrieve]

22. WHO Study Group. Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1985.

23. Groop L, Forsblom C, Lethovirta M, Tuomi T, Karanko S, Nissén M, Ehrnström B-O, Forsén B, Isomaa B, Snickars B, Taskinen M-R. Metabolic consequences of a family history of NIDDM (The Botnia Study) evidence for sex-specific parental effects. Diabetes. 1996;45:1585–1593.[Abstract]

24. Sambrooks J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbour; 1989.

25. Sidney S, Castellan NJ. The permutation test for paired replicates. In: Editions M-HI, ed. Nonparametric Statistics for the Behavioral Sciences: The Case of One Sample, Two Measures or Paired Replicates. 2nd ed. Singapore: McGraw-Hill Book Co; 1988:95–101.

26. Orho-Melander M, Almgren P, Kanninen T, Forsblom C, Groop LC. A paired-sibling analysis of the Xba1 polymorphism in the muscle glycogen synthase gene. Diabetologia. 1999;42:1138–1145.[Medline] [Order article via Infotrieve]

27. Kotanko P, Höglinger O, Skrabal F. ß2-Adrenoceptor density in fibroblast culture correlates with human NaCl sensitivity. Am J Physiol. 1992;263:C623–C627.[Abstract/Free Full Text]

28. Luft FC, Grim CE, Higgins JT, Weinberger MH. Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med. 1977;90:555–562.[Medline] [Order article via Infotrieve]

29. Kotanko P, Höglinger O, Binder A, Skrabal F. Further evidence for reduced beta2-adrenoceptor expression and modification of its density at a level beyond gene expression. Diabetologia. 1995;38:126–128.[Medline] [Order article via Infotrieve]

30. Liggett S. Functional properties of human ß2-adrenergic receptor polymorphisms. News Physiol Sci. 1995;10:265–273.[Abstract/Free Full Text]

31. Aynacioglu AS, Cascorbi I, Gungör K, Özkur M, Bekir N, Roots I, Brockmöller J. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu, and Thr164Ile polymorphisms in the ß2-adrenergic receptor among Turks. J Clin Pharmacol. 1999;48:761–764.

32. Meirhaeghe A, Helbecque N, Cottel D, Amoyel P. ß2-adrenoceptor gene polymorphism, body weight, and physical activity. Lancet. 1999;353:896. [Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Biol Res NursHome page
J. R. Dungan, Y. P. Conley, T. Y. Langaee, J. A. Johnson, S. M. Kneipp, P. J. Hess, and C. B. Yucha
Altered Beta-2 Adrenergic Receptor Gene Expression in Human Clinical Hypertension
Biol Res Nurs, July 1, 2009; 11(1): 17 - 26.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
T. Lucas, D. Losert, M. Allen, J. Halaschek-Wiener, B. Pratscher, C. Friedrich, M. Wolschek, G. Fuchsjager-Mayrl, L. Schmetterer, H. Pehamberger, et al.
Combination Allele-Specific Real-Time PCR for Differentiation of {beta}2-Adrenergic Receptor Coding Single-Nucleotide Polymorphisms
Clin. Chem., April 1, 2004; 50(4): 769 - 772.
[Full Text] [PDF]


Home page
Physiol. GenomicsHome page
J. H. Eisenach, A. M. McGuire, R. M. Schwingler, S. T. Turner, and M. J. Joyner
The Arg16/Gly {beta}2-adrenergic receptor polymorphism is associated with altered cardiovascular responses to isometric exercise
Physiol Genomics, February 13, 2004; 16(3): 323 - 328.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Dallongeville, N. Helbecque, D. Cottel, P. Amouyel, and A. Meirhaeghe
The Gly16->Arg16 and Gln27->Glu27 Polymorphisms of {beta}2-Adrenergic Receptor Are Associated with Metabolic Syndrome in Men
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4862 - 4866.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Castellano, F. Rossi, M. Giacche, C. Perani, F. Rivadossi, M. L. Muiesan, M. Salvetti, M. Beschi, D. Rizzoni, and E. Agabiti-Rosei
{beta}2-Adrenergic Receptor Gene Polymorphism, Age, and Cardiovascular Phenotypes
Hypertension, February 1, 2003; 41(2): 361 - 367.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
V. D Garovic, M. J Joyner, N. M Dietz, E. Boerwinkle, and S. T Turner
{beta}2-Adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans
J. Physiol., January 15, 2003; 546(2): 583 - 589.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Tomaszewski, N. J.R. Brain, F. J. Charchar, W. Y.S. Wang, B. Lacka, S. Padmanabahn, J. S. Clark, N. H. Anderson, H. V. Edwards, E. Zukowska-Szczechowska, et al.
Essential Hypertension and {beta}2-Adrenergic Receptor Gene: Linkage and Association Analysis
Hypertension, September 1, 2002; 40(3): 286 - 291.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. J. Ostgren, U. Lindblad, A. Melander, and L. Rastam
Survival in Patients With Type 2 Diabetes in a Swedish Community: Skaraborg Hypertension and Diabetes Project
Diabetes Care, August 1, 2002; 25(8): 1297 - 1302.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bengtsson, K.
Right arrow Articles by Groop, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bengtsson, K.
Right arrow Articles by Groop, L.
Related Collections
Right arrow Other hypertension
Right arrow Type 2 diabetes
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease